Related Experiment Video

Updated: Jul 14, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

[Pharmacokinetic-pharmacodynamics relationships of imatinib (Glivec)]

Catherine Delbaldo1

  • 1Service d'oncologie, Hôpital Henri-Mondor, 51 avenue du Maréchal de Lattre de Tassigny, 94010 Créteil Cedex, France. catherine.delbaldo@hmn.aphp.fr

Therapie
|June 22, 2007
PubMed

Insights

Imatinib effectively targets the proto-oncogene c-kit in gastrointestinal stromal tumors (GIST). Its pharmacokinetic profile in advanced GIST patients is linear and influenced by alpha-1-acid glycoprotein (AAG).

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Imatinib (Glivec) is a targeted therapy inhibiting tyrosine kinase receptors, notably the proto-oncogene c-kit.
  • The proto-oncogene c-kit is implicated in the development of gastrointestinal stromal tumors (GIST).

Purpose of the Study:

  • To analyze the pharmacokinetic (PK) profile of imatinib in patients with advanced GIST.
  • To investigate the role of alpha-1-acid glycoprotein (AAG) in imatinib's PK.

Main Methods:

  • Pharmacokinetic analysis in advanced GIST patients.
  • Assessment of imatinib metabolism via the cytochrome P450 enzyme system.
  • Evaluation of imatinib protein binding influenced by AAG.

Main Results:

  • Imatinib demonstrated linear pharmacokinetics in advanced GIST patients.
  • Imatinib undergoes extensive metabolism by the cytochrome P450 system.
  • Alpha-1-acid glycoprotein (AAG) significantly influences imatinib protein binding and PK.

Conclusions:

  • Imatinib exhibits predictable pharmacokinetics in advanced GIST.
  • AAG plays a crucial role in imatinib's pharmacokinetic behavior, impacting its efficacy and dosing.
  • Understanding imatinib PK and AAG interaction is vital for optimizing GIST treatment.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Related Concept Videos

Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship01:14

Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship

For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
Pharmacokinetic–Pharmacodynamic Relationship: Model Components01:14

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect01:26

Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect

The pharmacokinetic-pharmacodynamic (PK-PD) relationship describes the intricate link between drug exposure, efficacy, and toxicity, forming the foundation for optimal dosing regimens. This relationship uses mathematical modeling to characterize drug concentration-effect dynamics, ensuring precise therapeutic outcomes.Exposure represents the pharmacokinetic aspect of the PK-PD relationship, denoting the drug amount that elicits a biological response. It is typically quantified by administered...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Pharmacokinetic–Pharmacodynamic Relationship: Intensity of Dose-Effect Relationship01:23

Pharmacokinetic–Pharmacodynamic Relationship: Intensity of Dose-Effect Relationship

Pharmacodynamics explores the relationship between drug concentration and its effect. In a quantal response drug, the duration of action better correlates with drug concentration, while for graded effect drugs, the intensity of response is more relevant. This intensity depends on the dose, drug removal rate, and the region of the concentration–response curve.The concentration–response curve can be divided into three regions. Region 3 (80–100% maximum response) demonstrates that even as drug...